
ARTV Stock Forecast & Price Target
ARTV Analyst Ratings
Bulls say
Artiva Biotherapeutics is viewed favorably because AlloNK is showing encouraging early efficacy in Sjögren’s disease, an underappreciated indication with significant unmet need and no currently approved therapies. With 11 patients at ~6 months, the data show a -3.5-point mean ESSPRI improvement, robust ClinESSDAI gains, and mean stimulated salivary flow rising to ~1.1 mL/min, above the normal salivation range, while safety remains favorable across a 73-patient dataset with no ICANS, CRS, or GvHD reported. These results suggest a differentiated, community-friendly profile versus CAR T and TCE approaches, supporting the case that SjD could become the company’s next P3 focus after RA.
Bears say
Artiva Biotherapeutics is facing a severe deterioration in fundamentals after discontinuing AlloNK, its lead value driver, following two patient deaths and evidence of insufficient response durability, which halted Phase II and Phase III enrollment. The decision to cut roughly 94% of its workforce and evaluate strategic alternatives underscores that the company has lost its near-term growth engine and may struggle to create value from a pipeline that remains Phase II or earlier. Despite preliminary cash of $319.1 million as of Sep. 30, 2026 and about 50 million shares outstanding, the prospect of ~$125 million in severance and termination costs, plus the need for future financing amid intense competition and no approved NK cell therapies, supports a negative outlook.
This aggregate rating is based on analysts' research of Artiva Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ARTV Analyst Forecast & Price Prediction
Start investing in ARTV
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Artiva Biotherapeutics Inc (ARTV) Forecast
ARTV Analyst Forecast & Price Prediction
Start investing in ARTV
Order type
Buy in
Order amount
Est. shares
0 shares